- Home
- FGEN vs INKT Comparison
FGEN vs INKT Comparison
Compare FGEN & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGEN
- INKT
- Stock Information
- Founded
- FGEN 1993
- INKT 2017
- Country
- FGEN United States
- INKT United States
- Employees
- FGEN N/A
- INKT N/A
- Industry
- FGEN Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- FGEN Health Care
- INKT Health Care
- Exchange
- FGEN Nasdaq
- INKT Nasdaq
- Market Cap
- FGEN 33.5M
- INKT 28.8M
- IPO Year
- FGEN 2014
- INKT 2021
- Fundamental
- Price
- FGEN $7.44
- INKT $28.86
- Analyst Decision
- FGEN Strong Buy
- INKT Hold
- Analyst Count
- FGEN 1
- INKT 3
- Target Price
- FGEN $250.00
- INKT $37.50
- AVG Volume (30 Days)
- FGEN 66.4K
- INKT 2.7M
- Earning Date
- FGEN 08-05-2025
- INKT 08-12-2025
- Dividend Yield
- FGEN N/A
- INKT N/A
- EPS Growth
- FGEN N/A
- INKT N/A
- EPS
- FGEN N/A
- INKT N/A
- Revenue
- FGEN $6,996,000.00
- INKT N/A
- Revenue This Year
- FGEN N/A
- INKT N/A
- Revenue Next Year
- FGEN N/A
- INKT N/A
- P/E Ratio
- FGEN N/A
- INKT N/A
- Revenue Growth
- FGEN N/A
- INKT N/A
- 52 Week Low
- FGEN $4.50
- INKT $4.56
- 52 Week High
- FGEN $38.25
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- FGEN 64.36
- INKT 60.80
- Support Level
- FGEN $7.03
- INKT $6.80
- Resistance Level
- FGEN $5.73
- INKT $76.00
- Average True Range (ATR)
- FGEN 0.50
- INKT 5.95
- MACD
- FGEN 0.35
- INKT 3.73
- Stochastic Oscillator
- FGEN 100.00
- INKT 35.31
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.